,NURS 6521 Advanced Pharmacology
Exam Prep — Comprehensive Review +
Practice MCQs — Walden University
2025/2026
1. A nurse practitioner is teaching a graduate student about the core principles of pharmacology. Which
statement correctly distinguishes pharmacokinetics from pharmacodynamics?
A. Pharmacokinetics describes what the drug does to the body; pharmacodynamics describes what the body
does to the drug.
B. Pharmacokinetics describes what the body does to the drug; pharmacodynamics describes what the drug
does to the body.
C. Pharmacokinetics refers only to drug metabolism; pharmacodynamics refers only to drug excretion.
D. Pharmacokinetics and pharmacodynamics are interchangeable terms describing drug-receptor binding.
Correct Answer: B
Rationale: Pharmacokinetics encompasses absorption, distribution, metabolism, and excretion (what the body
does to the drug). Pharmacodynamics refers to the biochemical and physiologic effects of drugs on the body
(what the drug does to the body), including receptor binding and signal transduction .
2. A patient with decompensated heart failure and hepatic congestion is prescribed a medication that
undergoes extensive first-pass metabolism. The nurse practitioner anticipates that the oral bioavailability of
this drug will be:
A. Decreased because hepatic congestion reduces metabolic capacity
B. Increased because reduced hepatic blood flow allows more drug to reach systemic circulation
C. Unchanged because first-pass metabolism occurs only in the gastrointestinal tract
D. Decreased because heart failure reduces intestinal absorption
,Correct Answer: B
Rationale: In hepatic congestion and cirrhosis, hepatic blood flow and metabolic capacity are reduced,
impairing first-pass metabolism. A larger fraction of the oral dose reaches systemic circulation unchanged,
increasing bioavailability and potentially causing toxicity. Dose adjustments are often necessary .
3. A medication with a half-life of 6 hours is administered via continuous IV infusion. Approximately when will
the drug reach steady-state plasma concentration?
A. 6 hours
B. 12 hours
C. 24–30 hours
D. 48 hours
Correct Answer: C
Rationale: Steady-state concentration is achieved after approximately 4–5 half-lives. With a half-life of 6 hours,
steady state is reached in approximately 24–30 hours (4 × 6 = 24 to 5 × 6 = 30 hours). At steady state, the rate
of drug administration equals the rate of elimination .
4. A nurse practitioner is prescribing a drug known to be a potent inducer of CYP3A4. Which of the following
clinical consequences is most likely when this drug is added to a patient's regimen?
A. Increased plasma concentration of co-administered CYP3A4 substrates
B. Decreased plasma concentration of co-administered CYP3A4 substrates
C. No effect on co-administered drugs metabolized by CYP3A4
D. Immediate therapeutic effect of the inducer itself
Correct Answer: B
, Rationale: CYP3A4 inducers accelerate the metabolism of drugs that are CYP3A4 substrates, reducing their
plasma concentrations and potentially diminishing therapeutic effect. This is a classic drug-drug interaction
mechanism requiring monitoring and possible dose adjustment of the substrate drug .
5. A 72-year-old patient with a serum creatinine of 2.8 mg/dL and an estimated CrCl of 24 mL/min is prescribed
a renally eliminated medication with a narrow therapeutic index. The most appropriate prescribing adjustment
is to:
A. Maintain the standard dose and interval because therapeutic drug monitoring will detect toxicity
B. Increase the dose to compensate for reduced renal clearance
C. Reduce the dose and/or extend the dosing interval
D. Switch to an oral formulation to bypass renal elimination
Correct Answer: C
Rationale: For renally cleared drugs with a narrow therapeutic index, reduced renal clearance causes drug
accumulation and toxicity risk. Standard practice is to reduce the dose and/or extend the dosing interval based
on the degree of renal impairment (CrCl < 30 mL/min in this case) .
6. A patient is prescribed two medications that are both highly protein-bound (≥95%). The nurse practitioner
should monitor for:
A. Decreased therapeutic effect of both drugs
B. Increased free fraction and potential toxicity of one or both drugs
C. No interaction because protein binding is not clinically significant
D. Enhanced renal elimination of both drugs
Correct Answer: B
Exam Prep — Comprehensive Review +
Practice MCQs — Walden University
2025/2026
1. A nurse practitioner is teaching a graduate student about the core principles of pharmacology. Which
statement correctly distinguishes pharmacokinetics from pharmacodynamics?
A. Pharmacokinetics describes what the drug does to the body; pharmacodynamics describes what the body
does to the drug.
B. Pharmacokinetics describes what the body does to the drug; pharmacodynamics describes what the drug
does to the body.
C. Pharmacokinetics refers only to drug metabolism; pharmacodynamics refers only to drug excretion.
D. Pharmacokinetics and pharmacodynamics are interchangeable terms describing drug-receptor binding.
Correct Answer: B
Rationale: Pharmacokinetics encompasses absorption, distribution, metabolism, and excretion (what the body
does to the drug). Pharmacodynamics refers to the biochemical and physiologic effects of drugs on the body
(what the drug does to the body), including receptor binding and signal transduction .
2. A patient with decompensated heart failure and hepatic congestion is prescribed a medication that
undergoes extensive first-pass metabolism. The nurse practitioner anticipates that the oral bioavailability of
this drug will be:
A. Decreased because hepatic congestion reduces metabolic capacity
B. Increased because reduced hepatic blood flow allows more drug to reach systemic circulation
C. Unchanged because first-pass metabolism occurs only in the gastrointestinal tract
D. Decreased because heart failure reduces intestinal absorption
,Correct Answer: B
Rationale: In hepatic congestion and cirrhosis, hepatic blood flow and metabolic capacity are reduced,
impairing first-pass metabolism. A larger fraction of the oral dose reaches systemic circulation unchanged,
increasing bioavailability and potentially causing toxicity. Dose adjustments are often necessary .
3. A medication with a half-life of 6 hours is administered via continuous IV infusion. Approximately when will
the drug reach steady-state plasma concentration?
A. 6 hours
B. 12 hours
C. 24–30 hours
D. 48 hours
Correct Answer: C
Rationale: Steady-state concentration is achieved after approximately 4–5 half-lives. With a half-life of 6 hours,
steady state is reached in approximately 24–30 hours (4 × 6 = 24 to 5 × 6 = 30 hours). At steady state, the rate
of drug administration equals the rate of elimination .
4. A nurse practitioner is prescribing a drug known to be a potent inducer of CYP3A4. Which of the following
clinical consequences is most likely when this drug is added to a patient's regimen?
A. Increased plasma concentration of co-administered CYP3A4 substrates
B. Decreased plasma concentration of co-administered CYP3A4 substrates
C. No effect on co-administered drugs metabolized by CYP3A4
D. Immediate therapeutic effect of the inducer itself
Correct Answer: B
, Rationale: CYP3A4 inducers accelerate the metabolism of drugs that are CYP3A4 substrates, reducing their
plasma concentrations and potentially diminishing therapeutic effect. This is a classic drug-drug interaction
mechanism requiring monitoring and possible dose adjustment of the substrate drug .
5. A 72-year-old patient with a serum creatinine of 2.8 mg/dL and an estimated CrCl of 24 mL/min is prescribed
a renally eliminated medication with a narrow therapeutic index. The most appropriate prescribing adjustment
is to:
A. Maintain the standard dose and interval because therapeutic drug monitoring will detect toxicity
B. Increase the dose to compensate for reduced renal clearance
C. Reduce the dose and/or extend the dosing interval
D. Switch to an oral formulation to bypass renal elimination
Correct Answer: C
Rationale: For renally cleared drugs with a narrow therapeutic index, reduced renal clearance causes drug
accumulation and toxicity risk. Standard practice is to reduce the dose and/or extend the dosing interval based
on the degree of renal impairment (CrCl < 30 mL/min in this case) .
6. A patient is prescribed two medications that are both highly protein-bound (≥95%). The nurse practitioner
should monitor for:
A. Decreased therapeutic effect of both drugs
B. Increased free fraction and potential toxicity of one or both drugs
C. No interaction because protein binding is not clinically significant
D. Enhanced renal elimination of both drugs
Correct Answer: B
